Increased risk of cardiovascular disease and chronic kidney disease in NAFLD

Nature Reviews Gastroenterology and Hepatology

Volumn 9, Issue 7, 2012, Pages 372-381

  Bonora, Enzo ^a   Targher, Giovanni ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOLOGIST; CARDIOVASCULAR DISEASE; CHEMICAL ANALYSIS; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; DISEASE ASSOCIATION; DYSGLYCEMIA; DYSLIPIDEMIA; ECHOGRAPHY; ENDOCRINOLOGIST; GASTROENTEROLOGIST; GENERAL PRACTITIONER; HUMAN; HYPERTENSION; INCIDENCE; INSULIN RESISTANCE; INTERNIST; KIDNEY INJURY; NEPHROLOGIST; NONALCOHOLIC FATTY LIVER; OBESITY; PATIENT CODING; PHYSICIAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR;

CARDIOVASCULAR DISEASES; CHRONIC DISEASE; FATTY LIVER; HUMANS; INCIDENCE; KIDNEY DISEASES; PREVALENCE; RISK FACTORS;

EID: 84863489710     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2012.79     Document Type: Review

References (111)

1. Targher, G., Day, C. P. & Bonora, E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med. 363, 1341-1350 (2010).
2. Loria, P., Lonardo, A. & Targher, G. Is liver fat detrimental to vessels?: Intersections in the pathogenesis of NAFLD and atherosclerosis. Clin. Sci. (Lond.) 115, 1-12 (2008).
3. Targher, G., Marra, F. & Marchesini, G. Increased risk of cardiovascular disease in nonalcoholic fatty liver disease: Causal effect or epiphenomenon? Diabetologia 51, 1947-1953 (2008).
4. Ghouri, N., Preiss, D. & Sattar, N. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: A narrative review and clinical perspective of prospective data. Hepatology 52, 1156-1161 (2010).
5. Treeprasertsuk, S., Lopez-Jimenez, F. & Lindor, K. D. Nonalcoholic fatty liver disease and the coronary artery disease. Dig. Dis. Sci. 56, 35-45 (2011).
6. Targher, G., Chonchol, M., Zoppini, G., Abaterusso, C. & Bonora, E. Risk of chronic kidney disease in patients with non-Alcoholic fatty liver disease: Is there a link? J. Hepatol. 54, 1020-1029 (2011).
7. Ix, J. H. & Sharma, K. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: The roles of fetuin A, adiponectin, and AMPK. J. Am. Soc. Nephrol. 21, 406-412 (2010).
8. Angulo, P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 346, 1221-1231 (2002).
9. Vuppalanchi, R. & Chalasani, N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 49, 306-317 (2009).
10. Ratziu, V., Bellentani, S., Cortez-Pinto, H., Day, C. & Marchesini, G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J. Hepatol. 53, 372-384 (2010).
11. Torres, D. M. & Harrison, S. A. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 134, 1682-1698 (2008).
12. Mehta, S. R., Thomas, E. L., Bell, J. D., Johnston, D. G. & Taylor-Robinson, S. D. Non-invasive means of measuring hepatic fat content. World J. Gastroenterol. 14, 3476-3483 (2008).
13. Schwenzer, N. F. et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J. Hepatol. 51, 433-445 (2009).
14. Browning, J. D. Statins and hepatic steatosis: Perspectives from the Dallas Heart Study. Hepatology 44, 466-471 (2006).
15. Jimba, S. et al. Prevalence of non-Alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet. Med. 22, 1141-1145 (2005).
16. Targher, G. et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30, 1212-1218 (2007).
17. Williams, C. D. et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-Aged population utilizing ultrasound and liver biopsy: A prospective study. Gastroenterology 140, 124-131 (2011).
18. Marceau, P. et al. Liver pathology and the metabolic syndrome X in severe obesity. J. Clin. Endocrinol. Metab. 84, 1513-1517 (1999).
19. Gholam, P. M., Flancbaum, L., Machan, J. T., Charney, D. A. & Kotler, D. P. Nonalcoholic fatty liver disease in severely obese subjects. Am. J. Gastroenterol. 102, 399-408 (2007).
20. Machado, M., Mrquez-Vidal, P. A. & Cortez-Pinto, H. Hepatic histology in obese patients undergoing bariatric surgery. J. Hepatol. 45, 600-606 (2006).
21. De Ridder, R. J. et al. Review article: Non-Alcoholic fatty liver disease in morbidly obese patients and the effect of bariatric surgery. Aliment. Pharmacol. Ther. 26 (Suppl. 2), 195-201 (2007).
22. Fox, C. S. et al. Predictors of new-onset kidney disease in a community-based population. JAMA 291, 844-850 (2004).
23. Vlagopoulos, P. T. & Sarnak, M. J. Traditional and non-traditional cardiovascular risk factors in chronic kidney disease. Med. Clin. North Am. 89, 587-611 (2005).
24. Speliotes, E. K. et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: The Framingham Heart Study. Hepatology 51, 1979-1987 (2010).
25. Bonora, E. Relationship between regional fat distribution and insulin resistance. Int. J. Obes. Relat. Metab. Disord. 24 (Suppl. 2), S32-S35 (2000).
26. Bonora, E. The metabolic syndrome and cardiovascular disease. Ann. Med. 38, 64-80 (2006).
27. Grundy, S. M. Metabolic syndrome pandemic. Arterioscler. Thromb. Vasc. Biol. 28, 629-636 (2008).
28. Hwang, J. H. et al. Increased intrahepatic triglyceride is associated with peripheral insulin resistance: In vivo MR imaging and spectroscopy studies. Am. J. Physiol. Endocrinol. Metab. 293, E1663-E1669 (2007).
29. Koska, J. et al. Increased fat accumulation in liver may link insulin resistance with subcutaneous abdominal adipocyte enlargement, visceral adiposity, and hypoadiponectinemia in obese individuals. Am. J. Clin. Nutr. 87, 295-302 (2008).
30. Bonora, E. et al. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in Caucasian subjects from the general population: The Bruneck study. Diabetes Care 30, 318-324 (2007).
31. Kurella, M., Lo, J. C. & Chertow, G. M. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J. Am. Soc. Nephrol. 16, 2134-2140 (2005).
32. Kronenberg, F. Emerging risk factors and markers of chronic kidney disease progression. Nat. Rev. Nephrol. 5, 677-689 (2009).
33. Targher, G. et al. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Semin. Thromb. Hemost. 35, 277-287 (2009).
34. Targher, G. et al. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring) 16, 1394-1399 (2008).
35. Edens, M. A., Kuipers, F. & Stolk, R. P. Non-Alcoholic fatty liver disease is associated with cardiovascular disease risk markers. Obes. Rev. 10, 412-419 (2009).
36. Westerbacka, J. et al. Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin resistant subjects. Diabetes 56, 2759-2765 (2007).
37. Sookoian, S. et al. Liver transcriptional profile of atherosclerosis- related genes in human nonalcoholic fatty liver disease. Atherosclerosis 218, 378-385 (2011).
38. Yoneda, M. et al. High-sensitivity C reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J. Gastroenterol. 42, 573-582 (2007).
39. Wieckowska, A. et al. Increased hepatic and circulating interleukin 6 levels in human nonalcoholic steatohepatitis. Am. J. Gastroenterol. 103, 1372-1379 (2008).
40. Thuy, S. et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J. Nutr. 138, 1452-1455 (2008).
41. Villanova, N. et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 42, 473-480 (2005).
42. Targher, G. et al. Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: Role of visceral fat accumulation. Diabetes Care 27, 2498-2500 (2004).
43. Brea, A. et al. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis. A case-control study. Arterioscler. Thromb. Vasc. Biol. 25, 1045-1050 (2005).
44. Volzke, H. et al. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J. Gastroenterol. 11, 1848-1853 (2005).
45. Fracanzani, A. L. et al. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am. J. Med. 121, 72-78 (2008).
46. Sookoian, S. & Pirola, C. J. Non-Alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: A systematic review. J. Hepatol. 49, 600-607 (2008).
47. Petit, J. M. et al. Nonalcoholic fatty liver is not associated with carotid intima-media thickness in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 94, 4103-4106 (2009).
48. McKimmie, R. L. et al. Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: The Diabetes Heart Study. Am. J. Gastroenterol. 103, 3029-3035 (2008).
49. Targher, G. et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 29, 1325-1330 (2006).
50. Bonapace, S. et al. Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care 35, 389-395 (2012).
51. Perseghin, G. et al. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology 47, 51-58 (2008).
52. Mirbagheri, S. A., Rashidi, A., Abdi, S., Saedi, D. & Abouzari, M. Liver: An alarm for the heart? Liver Int. 27, 891-894 (2007).
53. Wong, V. W. et al. Coronary artery disease and cardiovascular outcomes in patients with non-Alcoholic fatty liver disease. Gut 60, 1721-1727 (2011).
54. Lautamäki, R. et al. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 291, E282-E290 (2006).
55. Ruttmann, E. et al. ?-glutamyltransferase as a risk factor for cardiovascular disease mortality: An epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation 112, 2130-2137 (2005).
56. Lee, D. H. et al. Serum ?-glutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28,838 middle-Aged men and women. Eur. Heart J. 27, 2170-2176 (2006).
57. Schindhelm, R. K. et al. Alanine aminotransferase predicts coronary heart disease events: A 10-year follow-up of the Hoorn Study. Atherosclerosis 191, 391-396 (2007).
58. Lee, D. S. et al. ?-glutamyltransferase and metabolic syndrome, cardiovascular disease, and mortality risk: The Framingham Heart Study. Arterioscler. Thromb. Vasc. Biol. 27, 127-133 (2007).
59. Wannamethee, S. G., Lennon, L. & Shaper, A. G. The value of ?-glutamyltransferase in cardiovascular risk prediction in men without diagnosed cardiovascular disease or diabetes. Atherosclerosis 201, 168-175 (2008).
60. Fraser, A. et al. ?-glutamyltransferase is associated with incident vascular events independently of alcohol intake: Analysis of the British Women's Heart and Health Study and meta-Analysis. Arterioscler. Thromb. Vasc. Biol. 27, 2729-2735 (2007).
61. Goessling, W. et al. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 135, 1935-1944 (2008).
62. Ruhl, C. E. & Everhart, J. E. Elevated serum alanine aminotransferase and ?-glutamyltransferase and mortality in the United States population. Gastroenterology 136, 477-485 (2009).
63. Strasak, A. M. et al. Longitudinal change in serum ?-glutamyltransferase and cardiovascular disease mortality: A prospective population-based study in 76,113 Austrian adults. Arterioscler. Thromb. Vasc. Biol. 28, 1857-1865 (2008).
64. Targher, G. Elevated serum ?-glutamyltransferase activity is associated with increased risk of mortality, incident type 2 diabetes, cardiovascular events, chronic kidney disease and cancer-A narrative review. Clin. Chem. Lab. Med. 48, 147-157 (2010).
65. Pompella, A., Emdin, M., Passino, C. & Paolicchi, A. The significance of serum ?-glutamyltransferase in cardiovascular diseases. Clin. Chem. Lab. Med. 42, 1085-1091 (2004).
66. Franzini, M. et al. Cardiovascular risk factors and ?-glutamyltransferase fractions in healthy individuals. Clin. Chem. Lab. Med. 48, 713-717 (2010).
67. Jepsen, P. et al. Prognosis of patients with a diagnosis of fatty liver-A registry-based cohort study. Hepatogastroenterology 50, 2101-2104 (2003).
68. Hamaguchi, M. et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J. Gastroenterol. 13, 1579-1584 (2007).
69. Haring, R. et al. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum ? glutamyl transpeptidase levels. Hepatology 50, 1403-1411 (2009).
70. Targher, G. et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 54, 3541-3546 (2005).
71. Targher, G. et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 30, 2119-2221 (2007).
72. Lazo, M. et al. Nonalcoholic fatty liver disease and mortality among US adults: Prospective cohort study. BMJ 343, d6891 (2011).
73. Matteoni, C. A. et al. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 116, 1413-1419 (1999).
74. Dam-Larsen, S. et al. Long-term prognosis of fatty liver: Risk of chronic liver disease and death. Gut 53, 750-755 (2004).
75. Adams, L. A. et al. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology 129, 113-121 (2005).
76. Rafiq, N. et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin. Gastroenterol. Hepatol. 7, 234-238 (2009).
77. Ekstedt, M. et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44, 865-873 (2006).
78. Söderberg, C. et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 51, 595-602 (2010).
79. Targher, G., Kendrick, J., Smits, G. & Chonchol, M. Relationship between serum ?-glutamyltransferase concentrations and chronic kidney disease in the United States population. Findings from the National Health and Nutrition Examination Survey 2001-2006. Nutr. Metab. Cardiovasc. Dis. 20, 583-590 (2010).
80. Yun, K. E., Shin, C. Y., Yoon, Y. S. & Park, H. S. Elevated alanine aminotransferase levels predict mortality from cardiovascular disease and diabetes in Koreans. Atherosclerosis 205, 533-537 (2009).
81. Targher, G. et al. Non-Alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia 51, 444-450 (2008).
82. Targher, G. et al. Nonalcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients. Diabetologia 53, 1341-1348 (2010).
83. Targher, G., Pichiri, I., Zoppini, G., Trombetta, M. & Bonora, E. Increased prevalence of chronic kidney disease in patients with type 1 diabetes and non-Alcoholic fatty liver. Diabet. Med. 29, 220-226 (2012).
84. Hwang, S. T. et al. Impact of nonalcoholic fatty liver disease on microalbuminuria in patients with prediabetes and diabetes. Intern. Med. J. 40, 437-442 (2010).
85. Yilmaz, Y. et al. Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: Association with liver fibrosis. Metabolism 59, 1327-1330 (2010).
86. Yasui, K. et al. Nonalcoholic steatohepatitis and increased risk of chronic kidney disease. Metabolism 60, 735-739 (2011).
87. Targher, G. et al. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin. J. Am. Soc. Nephrol. 5, 2166-2171 (2010).
88. Machado, M. V. et al. Impaired renal function in morbid obese patients with nonalcoholic fatty liver disease. Liver Int. 32, 241-248 (2012).
89. Lee, D. H., Jacobs, D. R. Jr, Gross, M. & Steffes, M. Serum ?-glutamyltransferase was differently associated with microalbuminuria by status of hypertension and diabetes: The Coronary Artery Risk Development in Young Adults (CARDIA) study. Clin. Chem. 51, 1185-1191 (2005).
90. Ryu, S., Chang, Y., Kim, D. I., Kim, W. S. & Suh, B. S. ?-glutamyltransferase as a predictor of chronic kidney disease in nonhypertensive and nondiabetic Korean men. Clin. Chem. 53, 71-77 (2007).
91. Arase, Y. et al. The development of chronic kidney disease in Japanese patients with non-Alcoholic fatty liver disease. Intern. Med. 50, 1081-1087 (2011).
92. Targher, G. et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J. Am. Soc. Nephrol. 19, 1564-1570 (2008).
93. Chang, Y. et al. Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. Metabolism 57, 569-576 (2008).
94. Badman, M. K. & Flier, J. S. The adipocyte as an active participant in the energy balance and metabolism. Gastroenterology 132, 2103-2115 (2007).
95. Shoelson, S. E., Herrero, L. & Naaz, A. Obesity, inflammation, and insulin resistance. Gastroenterology 132, 2169-2180 (2007).
96. Yki-Järvinen, H. Liver fat in the pathogenesis of insulin resistance and type 2 diabetes. Dig. Dis. 28, 203-209 (2010).
97. Cohen, J. C., Horton, J. D. & Hobbs, H. H. Human fatty liver disease: Old questions and new insights. Science 332, 1519-1523 (2011).
98. Stefan, N., Kantartzis, K. & Häring, H. U. Causes and metabolic consequences of fatty liver. Endocr. Rev. 29, 939-960 (2008).
99. Gastaldelli, A. et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 133, 496-506 (2007).
100. Fabbrini, E., Sullivan, S. & Klein, S. Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications. Hepatology 51, 679-689 (2010).
101. Kumashiro, N. et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc. Natl Acad. Sci. USA 108, 16381-16385 (2011).
102. Smith, B. W. & Adams, L. A. Nonalcoholic fatty liver disease and diabetes mellitus: Pathogenesis and treatment. Nat. Rev. Endocrinol. 7, 456-465 (2011).
103. Tilg, H. & Moschen, A. R. Insulin resistance, inflammation, and non-Alcoholic fatty liver disease. Trends Endocrinol. Metab. 19, 371-379 (2008).
104. Targher, G., Zoppini, G., Moghetti, P. & Day, C. P. Disorders of coagulation and hemostasis in abdominal obesity: Emerging role of fatty liver. Semin. Thromb. Hemost. 36, 41-48 (2010).
105. Luchtefeld, M. et al. Signal transducer of inflammation gp130 modulates atherosclerosis in mice and man. J. Exp. Med. 204, 1935-1944 (2007).
106. Fabbrini, E. et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc. Natl Acad. Sci. USA 106, 15430-15435 (2009).
107. Assy N., Djibren, A., Farah, R., Grosovski, M. & Marmor, A. Presence of coronary plaques in patients with nonalcoholic fatty liver disease. Radiology 254, 393-400 (2010).
108. Targher, G. et al. Prevalence of non-Alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J. Hepatol. 53, 713-718 (2010).
109. Targher, G., Pichiri, I., Zoppini, G., Trombetta, M. & Bonora, E. Increased prevalence of cardiovascular disease in type 1 diabetic patients with non-Alcoholic fatty liver disease. J. Endocrinol. Invest. http://dx.doi.org/10. 3275/7875.
110. Calori, G. et al. Fatty liver index and mortality: The Cremona study in the 15th year of follow-up. Hepatology 54, 145-152 (2011).
111. Bonora, E. et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: Studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 23, 57-63 (2000).